These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 14587861)

  • 21. Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
    Pritchard KI
    Ann Oncol; 2006 Jul; 17(7):1035-6. PubMed ID: 16766581
    [No Abstract]   [Full Text] [Related]  

  • 22. Risks and benefits of retinoids in the chemoprevention of cancer.
    de Palo G; Formelli F
    Drug Saf; 1995 Oct; 13(4):245-56. PubMed ID: 8573297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer and fenretinide, an analogue of vitamin A.
    Cobleigh MA
    Leukemia; 1994; 8 Suppl 3():S59-63. PubMed ID: 7808027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoprevention of breast cancer with fenretinide.
    Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
    IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
    [No Abstract]   [Full Text] [Related]  

  • 25. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
    Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
    J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological prevention of breast cancer: quo vadis?
    Serrano D; Bonanni B; Cazzaniga M; Galli A; Gonzaga AG; Decensi A
    Breast; 2003 Dec; 12(6):379-86. PubMed ID: 14659109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Meyskens FL
    J Natl Cancer Inst; 2000 Feb; 92(3):274-5. PubMed ID: 10655448
    [No Abstract]   [Full Text] [Related]  

  • 29. [-Results of ongoing breast cancer prevention studies-].
    Jungi WF
    Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
    [No Abstract]   [Full Text] [Related]  

  • 30. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Piantadosi S
    J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
    [No Abstract]   [Full Text] [Related]  

  • 31. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
    Veronesi U; De Palo G; Marubini E; Costa A; Mariani L; Formelli F; Decensi A
    J Natl Cancer Inst; 2000 Feb; 92(3):274; author reply 274-5. PubMed ID: 10655447
    [No Abstract]   [Full Text] [Related]  

  • 33. Preventive therapy for breast cancer: a consensus statement.
    Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
    Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies.
    Sogno I; Venè R; Ferrari N; De Censi A; Imperatori A; Noonan DM; Tosetti F; Albini A
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):2-14. PubMed ID: 20034809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fenretinide and risk reduction of second breast cancer.
    Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
    Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
    Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
    J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
    Darro F; Cahen P; Vianna A; Decaestecker C; Nogaret JM; Leblond B; Chaboteaux C; Ramos C; Pétein M; Budel V; Schoofs A; Pourrias B; Kiss R
    Breast Cancer Res Treat; 1998 Sep; 51(1):39-55. PubMed ID: 9877028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoprevention of breast cancer in the older patient.
    Minton SE
    Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinoids in the chemoprevention of bladder cancer.
    Sabichi AL; Lerner SP; Grossman HB; Lippman SM
    Curr Opin Oncol; 1998 Sep; 10(5):479-84. PubMed ID: 9800121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.